Remove Containment Remove Contamination Remove Engineer
article thumbnail

How API CMOs can improve containment capabilities without facility acquisition

Pharmaceutical Technology

According to GlobalData analysis, specialist small molecule API capabilities such as containment or controlled substances are driving large contract manufacturing organisations (CMOs) to acquire facilities. Flexible containment solutions for potent APIs. Partnering with containment experts.

article thumbnail

Mitigating the risks of cross-contamination during Oral Solid Dose (OSD) manufacturing

Pharmaceutical Technology

This heightens the risk of cross contamination, requiring effective containment solutions, especially when handling highly potent powders. These include extraction support systems, single-use liquid bags, ArmorFlex Films, continuous liners, contained powder transfer systems, bag in/bag out systems, and drum liners.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

API landscape in 2022: Drivers and solutions for small molecules

Pharmaceutical Technology

Research by GlobalData (Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition) shows that containment facilities are in high demand as the use of cytotoxic drugs continues to grow. Adding to these factors is that oncology accounts for the majority of marketed, contained drugs. Containment challenges.

article thumbnail

Study: safe drinking water remains out of reach for many Californians

Scienmag

Berkeley — An estimated 370,000 Californians rely on drinking water that may contain high levels of arsenic, nitrate or hexavalent chromium, and contaminated drinking water disproportionately impact communities of color in the state, finds a new analysis led by researchers at the University of California, Berkeley, and the University of California, (..)

article thumbnail

Risk Assessment for use of Engineered Genetic Materials in Clinical Research

Advarra

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. A key part of the IBC’s evaluation is assessing the risks posed by the engineered genetic materials. Why Does the IBC Need to do a Risk Assessment?

article thumbnail

SMi’s 6th Annual Highly Potent Active Pharmaceutical Ingredients

pharmaphorum

The expanding production of high potency APIs, along with the increase in associated toxicities, are driving requirements for more effective containment solutions and much-needed guidelines to ensure worker safety. Assess engineering containment controls, from isolators and barriers to fully automated lines.

article thumbnail

Cryomacs Freezing Bags – A Critical Component in the Successful Delivery of Biological Samples and Therapies

Roots Analysis

Due to the infrastructure available for processing, freezing and storing of these container systems, blood bags are the preferred container for cell therapy biopreservation. The above figure presents a general overview of the cryopreservation process.